Before compounds such as IL-1β neutralizing antibodies and IL-18 binding protein can be clinically applied, a deeper understanding of the biological mechanisms of NLRP3 activation, IL-18R- and IL-1R signaling, in regards to tumor progression is needed. The gene discussed is NLRP3; the disease is neoplasm.